[{"id":"43f66187-5b30-4357-8f5c-84f785cedc80","acronym":"POD1UM-204","url":"https://clinicaltrials.gov/study/NCT04463771","created_at":"2021-01-18T21:27:26.857Z","updated_at":"2024-07-02T16:34:37.736Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","source_id_and_acronym":"NCT04463771 - POD1UM-204","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • MSI • POLE","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation","tags":["PD-L1 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-06"},{"id":"29a2a8bd-7f56-4d48-a7d1-590b9ec36938","acronym":"","url":"https://clinicaltrials.gov/study/NCT04370704","created_at":"2021-01-18T21:07:06.059Z","updated_at":"2024-07-02T16:35:07.530Z","phase":"Phase 1/2","brief_title":"Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies","source_id_and_acronym":"NCT04370704","lead_sponsor":"Incyte Corporation","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2024-04-25"},{"id":"dccf2f76-76e4-4c57-9da3-30316fd549b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05287113","created_at":"2022-03-18T11:54:30.411Z","updated_at":"2024-07-02T16:35:17.799Z","phase":"Phase 2","brief_title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT05287113","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 09/15/2024","study_completion_date":" 09/15/2024","last_update_posted":"2024-02-23"},{"id":"c61284a7-7d3b-4a88-88a5-b1b30eda55b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03652077","created_at":"2021-01-18T17:55:26.755Z","updated_at":"2024-07-02T16:36:20.712Z","phase":"Phase 1","brief_title":"A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies","source_id_and_acronym":"NCT03652077","lead_sponsor":"Incyte Corporation","biomarkers":" HAVCR2","pipe":"","alterations":" ","tags":["HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e verzistobart (INCAGN2390)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 08/18/2021","primary_completion_date":" 08/18/2021","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2021-11-15"}]